Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis.
colonic tissue
disease activity
disease outcomes
eosinophils
peripheral blood
ulcerative colitis
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
05 01 2023
05 01 2023
Historique:
received:
14
01
2022
pubmed:
12
3
2022
medline:
11
1
2023
entrez:
11
3
2022
Statut:
ppublish
Résumé
It has been suggested that eosinophils may be a prognostic marker of disease outcome in ulcerative colitis (UC), but conflicting data exist. The objective was to investigate the extent of mucosal eosinophils and peripheral blood eosinophil count in newly diagnosed UC patients and to investigate its predictive value in short- and long-term disease outcomes. The degree of eosinophilia in baseline colonic biopsies and blood of newly diagnosed UC patients was retrospectively analyzed. It was investigated if tissue and blood eosinophilia could be a marker of a severe phenotype of UC, defined as the need for corticosteroids or immunomodulators in the first year or treatment with therapeutic monoclonal antibodies or colectomy during follow-up. Time to therapeutic monoclonal antibodies and time to colectomy were also evaluated as outcomes. There were 103 UC patients (median age 26 years) included. Median tissue peak eosinophil count (PEC) was 70.0 and median peripheral blood eosinophil count was 0.3 × 109/L at diagnosis. Tissue PEC (r = -0.161, P = .104) and blood eosinophil count (r = 0.022, P = .877) were not correlated with the severity of histologic inflammation. Logistic regression analyses did not identify PEC and blood eosinophil count as predictors of more severe disease outcomes. Tissue PEC and peripheral blood eosinophil count did not predict the time the initiation of therapeutic monoclonal antibodies or colectomy. Baseline tissue or peripheral blood eosinophils are not markers of disease activity and cannot be used as a predictor of severe disease outcomes in both adults and children with UC. Baseline tissue or peripheral blood eosinophils are not markers of disease activity and cannot be used as a predictor of severe disease outcomes in both adults and children with ulcerative colitis.
Sections du résumé
BACKGROUND
It has been suggested that eosinophils may be a prognostic marker of disease outcome in ulcerative colitis (UC), but conflicting data exist. The objective was to investigate the extent of mucosal eosinophils and peripheral blood eosinophil count in newly diagnosed UC patients and to investigate its predictive value in short- and long-term disease outcomes.
METHODS
The degree of eosinophilia in baseline colonic biopsies and blood of newly diagnosed UC patients was retrospectively analyzed. It was investigated if tissue and blood eosinophilia could be a marker of a severe phenotype of UC, defined as the need for corticosteroids or immunomodulators in the first year or treatment with therapeutic monoclonal antibodies or colectomy during follow-up. Time to therapeutic monoclonal antibodies and time to colectomy were also evaluated as outcomes.
RESULTS
There were 103 UC patients (median age 26 years) included. Median tissue peak eosinophil count (PEC) was 70.0 and median peripheral blood eosinophil count was 0.3 × 109/L at diagnosis. Tissue PEC (r = -0.161, P = .104) and blood eosinophil count (r = 0.022, P = .877) were not correlated with the severity of histologic inflammation. Logistic regression analyses did not identify PEC and blood eosinophil count as predictors of more severe disease outcomes. Tissue PEC and peripheral blood eosinophil count did not predict the time the initiation of therapeutic monoclonal antibodies or colectomy.
CONCLUSION
Baseline tissue or peripheral blood eosinophils are not markers of disease activity and cannot be used as a predictor of severe disease outcomes in both adults and children with UC.
Baseline tissue or peripheral blood eosinophils are not markers of disease activity and cannot be used as a predictor of severe disease outcomes in both adults and children with ulcerative colitis.
Autres résumés
Type: plain-language-summary
(eng)
Baseline tissue or peripheral blood eosinophils are not markers of disease activity and cannot be used as a predictor of severe disease outcomes in both adults and children with ulcerative colitis.
Identifiants
pubmed: 35275200
pii: 6547139
doi: 10.1093/ibd/izac044
pmc: PMC9825288
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62-69Informations de copyright
© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Saudi J Gastroenterol. 2011 May-Jun;17(3):194-8
pubmed: 21546723
Inflamm Bowel Dis. 2020 Nov 19;26(12):1890-1900
pubmed: 31960916
J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):573-6
pubmed: 26308316
J Immunol. 2008 Nov 15;181(10):7390-9
pubmed: 18981162
Dig Liver Dis. 2017 Feb;49(2):170-174
pubmed: 27903418
Neurogastroenterol Motil. 2021 Jul;33(7):e14072
pubmed: 33426755
Adv Med Sci. 2012;57(2):230-6
pubmed: 22968338
Dig Dis Sci. 1987 Apr;32(4):363-7
pubmed: 2881741
Gut. 2008 Mar;57(3):331-8
pubmed: 17981888
Histopathology. 1996 Jan;28(1):1-13
pubmed: 8838115
J Pediatr Gastroenterol Nutr. 2011 Jun;52(6):650-61
pubmed: 21593640
Scand J Gastroenterol. 1970;5(6):485-90
pubmed: 5460410
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
J Immunol. 2014 Aug 1;193(3):999-1005
pubmed: 25049430
Lancet. 1997 Oct 11;350(9084):1105
pubmed: 10213581
Gut. 2000 Sep;47(3):404-9
pubmed: 10940279
J Crohns Colitis. 2020 Nov 7;14(11):1503-1511
pubmed: 32504534
J Crohns Colitis. 2020 Feb 10;14(2):169-175
pubmed: 31504348
Scand J Gastroenterol. 1979;14(4):395-9
pubmed: 482851
Tech Coloproctol. 2018 Dec;22(12):941-946
pubmed: 30535522
J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1202-13
pubmed: 7798561
Inflamm Bowel Dis. 2020 Jul 17;26(8):1232-1238
pubmed: 31633167
Colorectal Dis. 2014 Dec;16(12):O420-30
pubmed: 25040651
Dig Dis Sci. 2013 Jan;58(1):222-8
pubmed: 22855293
J R Soc Med. 2007 Mar;100(3):151-2
pubmed: 17339311
Best Pract Res Clin Gastroenterol. 2008;22(3):537-49
pubmed: 18492570
J Crohns Colitis. 2013 Nov;7(10):827-51
pubmed: 23870728
Am J Gastroenterol. 2017 Dec;112(12):1849-1858
pubmed: 29112200
Hum Pathol. 2008 Jun;39(6):832-6
pubmed: 18430454
J Allergy Clin Immunol Pract. 2020 Jun;8(6):1994-2003.e2
pubmed: 32061717
Gut. 1979 Sep;20(9):787-91
pubmed: 499919
Scand J Gastroenterol. 2002 Feb;37(2):200-5
pubmed: 11843058
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):855-868
pubmed: 28939374
Mod Pathol. 1997 Apr;10(4):363-5
pubmed: 9110299
Gut. 2005 Dec;54(12):1714-20
pubmed: 15886302